AR092532A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents
Etanercept correctamente plegado de alta pureza y excelente rendimientoInfo
- Publication number
- AR092532A1 AR092532A1 ARP130103250A ARP130103250A AR092532A1 AR 092532 A1 AR092532 A1 AR 092532A1 AR P130103250 A ARP130103250 A AR P130103250A AR P130103250 A ARP130103250 A AR P130103250A AR 092532 A1 AR092532 A1 AR 092532A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- folded
- correctly folded
- etanercept
- mixed mode
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699552P | 2012-09-11 | 2012-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092532A1 true AR092532A1 (es) | 2015-04-22 |
Family
ID=50233493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103250A AR092532A1 (es) | 2012-09-11 | 2013-09-11 | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US20140072560A1 (https=) |
| EP (1) | EP2895188B1 (https=) |
| JP (3) | JP2015533797A (https=) |
| KR (2) | KR102250937B1 (https=) |
| CN (2) | CN104902914B (https=) |
| AR (1) | AR092532A1 (https=) |
| AU (2) | AU2013315750B9 (https=) |
| BR (1) | BR112015005161A2 (https=) |
| CA (1) | CA2882551A1 (https=) |
| CL (1) | CL2015000572A1 (https=) |
| CO (1) | CO7400876A2 (https=) |
| CY (1) | CY1120062T1 (https=) |
| DK (1) | DK2895188T3 (https=) |
| DO (1) | DOP2015000055A (https=) |
| EA (1) | EA031324B1 (https=) |
| EC (1) | ECSP15014138A (https=) |
| ES (1) | ES2657377T3 (https=) |
| HR (1) | HRP20180182T1 (https=) |
| HU (1) | HUE036524T2 (https=) |
| IL (2) | IL237311B (https=) |
| IN (1) | IN2015KN00452A (https=) |
| LT (1) | LT2895188T (https=) |
| MX (2) | MX360044B (https=) |
| NO (1) | NO2972131T3 (https=) |
| PE (2) | PE20200607A1 (https=) |
| PL (1) | PL2895188T3 (https=) |
| PT (1) | PT2895188T (https=) |
| RS (1) | RS57013B1 (https=) |
| SG (1) | SG11201501460RA (https=) |
| SI (1) | SI2895188T1 (https=) |
| SM (1) | SMT201800163T1 (https=) |
| TW (2) | TWI609877B (https=) |
| WO (1) | WO2014043103A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| HK1200718A1 (en) | 2011-10-18 | 2015-08-14 | 科荣生生物科学公司 | Etanercept formulations stabilized with sodium chloride |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| EA031324B1 (ru) * | 2012-09-11 | 2018-12-28 | Кохерус Байосайенсис, Инк. | Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода |
| AU2015273049B2 (en) * | 2014-06-13 | 2019-11-14 | Lupin Limited | Process for the purification of TNFR:Fc fusion protein |
| ES2733298T3 (es) | 2014-07-18 | 2019-11-28 | Sandoz Ag | Cuantificación de TNFR2:Fc plegado erróneamente |
| EP3241849A4 (en) * | 2014-12-31 | 2018-06-20 | LG Chem, Ltd. | Method for producing tnfr-fc fusion protein containing target content of impurities |
| KR20170138426A (ko) | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| SG11201804083QA (en) * | 2015-11-18 | 2018-06-28 | Merck Patent Gmbh | Opposite ph-salt gradients for improved protein separations |
| US20180327447A1 (en) * | 2015-11-18 | 2018-11-15 | Merck Patent Gmbh | Improved protein separation in ion exchange chromatography |
| CN109563124A (zh) * | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | 多特异性抗体的纯化 |
| AU2017345490B2 (en) * | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CA3057286A1 (en) * | 2017-03-24 | 2018-09-27 | Council Of Scientific And Industrial Research | A process for the purification of recombinant antibody fragments |
| US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| EP4142792A4 (en) | 2020-05-01 | 2024-11-27 | Kashiv Biosciences, LLC | An improved process of purification of protein |
| US20240156907A1 (en) * | 2021-03-16 | 2024-05-16 | Kashiv Biosciences, Llc | Novel formulation of fusion protein |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| CN118414350A (zh) * | 2021-10-19 | 2024-07-30 | 阿特根公司 | 纯化具有igg fc结构域的融合蛋白的方法 |
| EP4696709A1 (en) * | 2024-12-06 | 2026-02-18 | Qilu Pharmaceutical Co., Ltd. | Variants of etanercept and related processes |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| AU4363200A (en) | 1999-04-19 | 2000-11-02 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2001058473A1 (en) | 2000-02-10 | 2001-08-16 | Wyeth | Method of treating or inhibiting cellular injury or cell death |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| JP2005505494A (ja) | 2001-02-23 | 2005-02-24 | イミュネックス・コーポレーション | 活性タンパク質の回収増加 |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
| US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| JP4980048B2 (ja) | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| US20060177444A1 (en) | 2003-03-20 | 2006-08-10 | Tatsuo Horizoe | Concomitant drug as therapeutic agent for inflammatory bowel disease |
| SG145712A1 (en) | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| HRP20130098T1 (hr) | 2003-10-14 | 2013-02-28 | F. Hoffmann - La Roche Ag | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a |
| AU2005216847B2 (en) * | 2004-02-27 | 2010-04-01 | Cytiva Bioprocess R&D Ab | A process for the purification of antibodies |
| JP5554466B2 (ja) | 2004-03-01 | 2014-07-23 | 味の素株式会社 | 抗ヒトＴＮＦ−α抗体活性低下抑制剤 |
| CA2557046A1 (en) | 2004-03-05 | 2005-10-13 | John Crowley | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| JP5339901B2 (ja) | 2005-05-10 | 2013-11-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 炎症傷害の処置および評価 |
| KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| CN101584858A (zh) | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| BRPI0620316A2 (pt) | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| JP2009534390A (ja) | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| EP2064315B1 (en) | 2006-11-03 | 2015-05-13 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
| JP5577098B2 (ja) | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| US7691980B2 (en) * | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| CA2679941C (en) | 2007-03-02 | 2016-09-20 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| EP2170390B1 (en) | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
| TWI543768B (zh) | 2007-11-30 | 2016-08-01 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| US20110129468A1 (en) * | 2008-02-29 | 2011-06-02 | Biogen Idec Ma Inc. | Purified immunoglobulin fusion proteins and methods of their purification |
| JP5677943B2 (ja) * | 2008-06-05 | 2015-02-25 | アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ | ポリペプチド |
| WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| US8536316B2 (en) | 2009-08-07 | 2013-09-17 | Emd Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| CN104059955A (zh) | 2009-08-11 | 2014-09-24 | 弗·哈夫曼-拉罗切有限公司 | 在无谷氨酰胺的细胞培养基中的蛋白质生产 |
| US20120208986A1 (en) * | 2009-10-20 | 2012-08-16 | Wenger Marc D | Use of mixed mode chromatography for the capture and purification of basic antibody products |
| US20130052195A1 (en) | 2009-12-23 | 2013-02-28 | Emergent Product Development Seattle,LLC | Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof |
| US9428727B2 (en) | 2010-04-26 | 2016-08-30 | Novartis Ag | Cell culture medium |
| EP2568960B1 (en) * | 2010-05-10 | 2018-06-06 | Intas Pharmaceuticals Ltd. | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin |
| EP2598167B1 (en) | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| EP2606119A1 (en) | 2010-08-20 | 2013-06-26 | Wyeth LLC | Cell culture of growth factor-free adapted cells |
| EP2611904A2 (en) | 2010-08-31 | 2013-07-10 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
| WO2012051147A1 (en) * | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| BR112013026883A2 (pt) | 2011-04-20 | 2021-12-07 | Sandoz Ag | Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| CN113244374A (zh) | 2011-07-01 | 2021-08-13 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
| DK2726600T3 (en) | 2011-07-01 | 2017-05-15 | Amgen Inc | Mammalian Cell Culture |
| BR112014000352A2 (pt) * | 2011-07-08 | 2017-02-14 | Merck Sharp & Dohe Corp | método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada |
| KR101454316B1 (ko) * | 2011-08-17 | 2014-10-27 | 한화케미칼 주식회사 | 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법 |
| US10485869B2 (en) * | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| HK1200718A1 (en) * | 2011-10-18 | 2015-08-14 | 科荣生生物科学公司 | Etanercept formulations stabilized with sodium chloride |
| IN2015KN00005A (https=) * | 2012-07-09 | 2015-07-31 | Coherus Biosciences Inc | |
| EA031324B1 (ru) * | 2012-09-11 | 2018-12-28 | Кохерус Байосайенсис, Инк. | Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода |
| EP3175282B1 (en) * | 2014-07-31 | 2021-06-09 | Mtt Innovation Incorporated | Numerical approaches for free-form lensing: area parameterization free-form lensing |
| US20160108634A1 (en) * | 2014-10-16 | 2016-04-21 | Ronald Uphold | Pool Cover Hanger Device |
-
2013
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-10 SM SM20180163T patent/SMT201800163T1/it unknown
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en not_active Ceased
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko not_active Expired - Fee Related
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko not_active Expired - Fee Related
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh not_active IP Right Cessation
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh not_active IP Right Cessation
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
-
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
-
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
-
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en not_active Expired - Fee Related
-
2018
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-17 US US16/443,688 patent/US10947306B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,514 patent/US10954293B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,721 patent/US10954295B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,594 patent/US10954294B2/en not_active Expired - Fee Related
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
-
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092532A1 (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| WO2014141152A3 (en) | Low concentration antibody formulations | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| MX2018014228A (es) | Proteina de union de albumina sérica de dominio unico. | |
| CY1121895T1 (el) | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA201892693A1 (ru) | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 | |
| PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| EA201791350A9 (ru) | Радиофармацевтические комплексы | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| BR112018017174A2 (pt) | conjugados de aminoácido e peptídeo e processo de conjugação | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| MX2018013685A (es) | Terapia de combinacion de cebadadura:refuerzo. | |
| CO2023004265A2 (es) | Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped | |
| WO2013111012A3 (en) | Methods and compositions for therapeutic agents | |
| BR112012022292A2 (pt) | método para produção da proteína recombinante interferon solúvel sem desnaturação. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |